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HCT is a common treatment for patients with high risk or
relapsed AML or ALL, although speciﬁc late effects in AML or
ALL survivors after HCT have not been well described. The
BMT-SS is a retrospective cohort study in which participants
completed a 255 item questionnaire on late effects occurring
after HCT. Eligible subjects received HCT between 1974-1998,
were 18 years or older at the time of interview and had survived
for 2 yrs after HCT. A random sample of 319 siblings of study
participants was recruited for comparison. The study included
253 survivors with AML and 100 with ALL. Mean age at HCT
was 32yr AML/22yr ALL (1.7-63yr), and the mean age at
interview was 41yr AML/34yr ALL (18-67yr), and 44yr (19-
79yr) for siblings. Subjects survived a mean of 10yr (2-25yr)
after HCT. Donor source was related (57% AML, 75% ALL),
autologous (35% AML, 18% ALL) or unrelated (8% AML, 7%
ALL); 82% from marrow, 17% from peripheral blood /-
marrow, and 0.8% cord blood. 82% of AML and 100% of ALL
subjects received TBI. The frequencies of late effects did not
differ between ALL and AML survivors. Compared to siblings,
survivors had a signiﬁcantly higher frequency of diabetes (DM,
9% vs 3%, p0.001), hypothyroidism (22% vs 7%, p0.001),
osteoporosis (9% vs 2%, p0.001), exercise induced shortness
of breath (EISB, 7% vs 2%, p0.006, neurosensory impair-
ments (30% vs 20%, p0.001), and problems with balance,
tremor or weakness (14% vs 5%, p0.001). Survivors also
reported signiﬁcantly higher frequency of requiring assistance
with activities of daily living, and having their health status
prevent school or work attendance. In multivariable analysis, the
risk of these outcomes did not differ by diagnosis. Survivors
after allogeneic HCT had higher odds of DM (odds ratio [OR]
3.92, 95% conﬁdence interval [CI] 1.09-14.01), osteoporosis
(OR 3.1, 95% CI 1.02-9.43), cardiopulmonary impairments
(OR 1.93, 95% CI 1.1-3.38), and abnormal sense of touch (OR
2.55, 95% CI 1.19-5.45) and were also more likely to have
difﬁculties with routine activities (OR 4.63, 95% CI 1.30-
16.54), and to report their overall health as fair or poor (OR
2.15, 95% CI 1.09-4.24). Those with a history of chronic
GVHD had signiﬁcantly higher odds of having EISB, neuro-
sensory impairments, and inability to attend school or work due
to their health. Ongoing surveillance for these late effects and
appropriate interventions are required to improve the health
status of ALL and AML survivors after HCT.
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ACCESS TO HEMATOPOIETIC STEM CELL TRANSPLANTATION: EFFECT
OF RACE AND GENDER
Joshua, T.V.1, Rizzo, J.D.1, Zhang, M.-J.1, Horowitz, M.M.1 1Center
for International Blood and Marrow Transplant Research, Medical Col-
lege of Wisconsin, Milwaukee, WI.
Background
Although Hematopoietic Stem Cell Transplantation (HCT)
has the potential to increase survival for patients with many
diseases, particularly hematologic cancers, it is a complex and
costly procedure with substantial risk of morbidity and mortal-
ity. Increasing numbers of uninsured and underinsured persons
and health care marketplace competition raise concerns about
patients’ access to HCT in the United States. Many studies
demonstrate that African-Americans are more likely to be diag-
nosed at advanced stages of cancer and are less likely to receive
optimal care for cancer than Caucasians and that women are less
likely to receive some aggressive interventions than men. In this
study, we addressed the question of whether African-Americans
and women are would be less likely to receive HCT for hema-
tologic malignancy.
Methods
We estimated the annual incidence of leukemia, lymphoma
and multiple myeloma for African-Americans, Caucasians, men
and women under the age of 70 years in the U.S. using the
SEER Cancer Registry and U.S. Census reports. We estimated
the annual incidence of autologous, HLA-identical sibling and
unrelated HCT performed in these groups in the U.S. using
CIBMTR registration data for 1997 to 2002. Logistic regression
was used to calculate the age-adjusted odds ratio of receiving
HCT in groups deﬁned by race, gender and disease.
Results
The overall likelihood (or odds) of undergoing HCT for the
diseases considered was higher for Caucasians than for African-
Americans [OR1.40(1.34-1.46)]. This difference in likelihood
persisted for each type of HCT: autologous [OR1.24(1.19-
1.30)], HLA identical sibling [OR1.59(1.46-1.74)], and unre-
lated donor [OR2.02(1.75-2.33)]. Men were somewhat more
likely to receive HCT than women [OR1.07(1.05-1.1)]; how-
ever, this difference pertained only to autologous transplanta-
tion [OR1.1(1.06-1.13)]. The likelihoods of HLA identical
sibling [OR1.05(0.99-1.10)] and unrelated donor HCT
[OR0.94(0.88-1.01)] did not differ signiﬁcantly by gender.
Conclusions
Utilization of HCT for leukemia, lymphoma and multiple my-
eloma varies by race, with Caucasians more likely to receive HCT
than African-Americans. Lower HCT rates for African-Americans
were seen for both autologous and allogeneic HCT, indicating that
donor availability cannot fully explain the differences. Women
with lymphoma and multiple myeloma are also less likely than men
to receive autologous HCT for reasons unexplained by age or
disease status.
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HEMATOPOIETIC CELL TRANSPLANTATION-COMORBIDITY INDEX
(HCT-CI): A VALID TOOL TO PREDICT MORBIDITY RISK IN PATIENTS
UNDERGOING AUTOLOGOUS HCT (AHCT) FOR LYMPHOMA
Kassar, M.1, Shell, K.1, Gregory, S.A.1, Venugopal, P.1, Shammo, J.1,
Fung, H.C.1 1Rush University Medical Center, Chicago, IL.
Background: HCT-CI provided valid scoring of pretrans-
plant comorbidities that predicted non-relapse mortality and
survival for patients (pts) undergoing allogeniec HCT. It is
more sensitive and greater survival predictor than Charlson
Comorbidity Index (CCI). (Ref: M. Sorror et al, Blood Oct/05,
Vol 106). Objectives: To evaluate the predictive value of
HCT-CI and CCI for morbidity risk assessment in pts with
lymphoma undergoing AHCT. Morbidity was measured by the
duration of hospitalization (DOH) and the incidence of Hospi-
tal Re-Admission within 100 days post-AHCT (HRA-100).
Methods: We included pts with history of Hodgkin or non-
Hodgkin lymphoma (HL or NHL) who underwent AHCT in
our institution between 01/98 and 05/06. Since the prevalence
of comorbidities is less before the age of 40, only pts above this
age were included. Pts were given scores based on the HCT-CI
and CCI (table). Prior solid tumor comorbidity was excluded.
Results: 80 pts met the inclusion criteria , 74 had NHL and 6
had HL. 61 pts were male. Median age was 56 years (42-76).
Median DOH was 21 days (12-36). Median HCT-CI was 1: 37
% of pts had score 0, 26% had score 1, and 37 % had scores 2
to 7. Median CCI was 1: 46% of pts had score 0, 31% had score
1, and 23% had scores 2 to 3. 16 pts (20%) required HRA-100.
After adjustment for age at transplantation and type of condi-
tioning regimens, HCT-CI was signiﬁcantly correlated with the
DOH (p0.027, HR: 0.86), whereas the CCI was not (p 0.06,
HR: 0.79). Both HCT-CI and CCI were signiﬁcant predictors
for HRA-100 (p0.009, OR: 1.51; p 0.017, OR: 2.08, respec-
tively). Conclusion: HCT-CI predicted the morbidity risk after
AHCT for pts with lymphoma. Both HCT-CI and CCI were
strong predictors for the risk of HRA-100. HCT-CI is more
valid and reliable than CCI in predicting the DOH. HCT-CI
can serve as important tool for both the transplant administrator
when planning for resources allocation, and for patients during
pre-transplant evaluation and counseling.
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HCT-CI Comorbidities and their corresponding HCT-CI and CCI
scores
Comorbidity
Prevalence:
No. of pts
(%)
HCT-CI
score CCI score
Hepatic (mild) 11 (13.8) 1 1
Cardiac 12 (15) 1 1
Cerebrovascular disease 3 (3.8) 1 1
Arrhythmia 7 (8.8) 1 0
Pulmonary (moderate) 9 (11.3) 2 1
Pulmonary (severe) 6 (7.5) 3 1
Rheumatologic 4 (5) 2 1
Diabetes 18 (22.5) 1 1
Inflammatory bowel disease 2 (2.5) 1 0
Renal dysfunction
(moderate/severe) 1 (1.3) 2 2
Psychiatric disturbance 9 (11.3) 1
Not
included
Infection 5 (6.3) 1
Not
included
Obesity 9(11.3) 1
Not
included
Peptic ulcer disease 0(0) 2 1
Hepatic (moderate/severe) 0(0) 3 3
Heart valve disease 0(0) 3 0
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ALLOANATIGENIC REACTIONS AFTER HEMATOPOIETIC CELL TRANS-
PLANTATION (HCT) INDUCE GENOMIC ALTERATIONS IN EPITHELIAL
CELLS AS SHOWN IN HUMAN STUDIES AND IN AN IN VITRO MODEL
Spyridonidis, A.1, Faber, P.2, Petrikkos, L.2, Bertz, H.2, Finke, J.2
1Hematology, Patras University Hospital, Rio-Patras, Greece; 2Hema-
tology-Oncology, Freiburg University Medical Center, Freiburg, Ger-
many.
We previously demonstrated frequent genomic alterations mea-
sured by microsatellite instability (MSI) in non-neoplastic epithe-
lial tissues of pts who underwent allogeneic HCT (Blood 2006;
107:3389-3396). These genomic alterations were found only after
allogeneic but not after autologous HCT, and therefore we hy-
pothesized that an allogeneic effect is substantially involved in the
mutation process. We extended our previous analyses by examin-
ing 210 bucall swabs obtained from 70 pts between day (d) 26 and
d3514 after allogeneic HCT for the presence of MSI. MSI was
found in the buccal smears of 38% allografted patients. In a
prospective trial, in which pts were followed from time before
HCT until d365, 5 out of 14 (35%) pts exhibited MSI post-HCT
although all showed stable microsatellites before transplantation.
Statistical analyses in order to identify which clinical factors inﬂu-
ence the presence of MS are in progress. To test the hypothesis
that an alloantigenic effect is responsible for th induction of MSI,
we developed a model system in which keratinocyte (HaCaT) cells
were transfected with a plasmid vector which carries a G418 se-
lectable marker and a microsatellite repeat (CA) that places the
sequence for Hygromycin Resistance (HygR) out of frame for
protein translation. DNA slippage mutations can restore the HygR
reading frame and become detectable as HygR colonies. Pools of
stably transfected HaCaT cells were treated with supernatant (SN)
of major histocompatibility complex nonmatched mixed lympho-
cyte cultures (MLC) and assayed for HygR colonies 48h later.
We found that HaCaT cells aquire hygromycin resistance after
treatment with supernatatant from MLC. Treatment of cells with
hydrogen hyperoxid which has been shown in a E. Coli system to
induce MSI generated HygR colonies at a 80% lower fre-
quency than the SN-MLC treatment. Control cells transfected
with an in-frame hygromycin B gene construct (p12) were grown
with high efﬁciency in the presence of hygromycin B. In summary,
our in vivo data conﬁrm our previous results and provide evidence
of genomic alterations after allogeneic HCT and our in vitro data
are compatible with the hypothesis that an alloantigenic factor is
the driving force in producing detectable MSI in the allografted
patients. Elucidating the ultimate mechanisms underlying the
genomic instability following allogeneic HCT may prove to be of
major therapeutic value.
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QUANTIFYING THE SURVIVAL BENEFIT OF ALLOGENEIC STEM CELL
TRANSPLANT IN THE MANAGEMENT OF RELAPSED ACUTE MYELOID
LEUKEMIA
Armistead, P.M.1, De Lima, M.1, Pierce, S.1, Giralt, S.1,
Champlin, R.1, Estey, E.1 1MD Anderson Cancer Center, Houston, TX.
Outcomes data comparing patients with relapsed acute myeloid
leukemia (AML) who undergo transplant versus traditional che-
motherapy alone are limited, due primarily to difﬁculty obtaining
adequate patient sample sizes. To address these issues, a retrospec-
tive chart review was performed on all AML patients (n600)
treated at ﬁrst relapse at MD Anderson Cancer Center from 1995
through 2004. Median age was 58 (range 15-85, 66% of patients
50), and poor risk cytogenetics (-5 or -7 deletions) were present
in 23%. 139 (23%) patients achieved a second complete remission
(CR2), 64 (11%) patients died during salvage chemotherapy, and
397 (66%) patients were resistant to therapy. Remission duration
and overall survival were compared between patients in second
remission who underwent allogeneic transplant and only those
patients who did not undergo transplant because of patient pref-
erence or lack of a suitable donor.
Of the 102 patients who achieved a CR2 and were evaluated for
tranplant, 72 (71%) underwent transplant and 30 (29%) did not.
Twenty-one of the 30 patients not undergoing transplant declined
the procedure or did not have a suitable donor. There was a
statistically signiﬁcant difference in remission duration favoring
the transplant cohort (2-year actuarial relapse-free survival of 46%
vs. 13%, p0.007), and a trend toward overall survival beneﬁt
(2-year actuarial survival 44% vs. 23%, p0.105). Differences is
relapse-free and overall survival for patients 50 years old (n24
patients transplanted vs. 14 patients not transplanted) were not
statistically signiﬁcant (2 year relapse-free survival 50% vs. 15%,
p0.373; 2-year overall survival 43% vs. 23%, p0.832).
Of the 239 patients resistant to their ﬁrst salvage regimen who
underwent a transplant evaluation, 105 (44%) patients underwent
allogeneic transplant while 71 (30%) patients did not because of
lack of an available donor. A signiﬁcant survival advantage was
noted in the cohort of patients undergoing transplant (2-year
actuarial survival 13% vs. 0%, p0.001). This beneﬁt was also
observed in patients in the cohort who were 50 years old (2-year
actuarial survival 12% vs. 0%, p0.001).
Allogeneic transplant at the time of second remission or failed
ﬁrst salvage is a feasible strategy in many patients (30% of patients
in this cohort). Given the large number of AML patients who will
need salvage therapy, greater efforts should be made in identifying
donors prior to the patient’s ﬁrst relapse.
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OUTCOMES FOR ALLOGENEIC TRANSPLANTATION IN IMATINIB-RE-
FRACTORY CHRONIC MYELOID LEUKAEMIA (CML) ARE EQUIVALENT
TO OUTCOMES IN IMATINIB-RESPONSIVE/IMATINIB-NAIVE CML AND
CAN BE PREDICTED BY THE EBMT RISK SCORE
Durrant, S.T.1, Stylian, S.1, Western, R.J.1, Morton, J.P.1, Butler, J.1,
Hutchins, C.1, Hill, G.1, Kennedy, G.A.1 1Royal Brisbane Hospital,
Brisbane, Queensland, Australia.
Aims: To review the outcome of allogeneic stem cell transplan-
tation (SCT) in imatinib refractory chronic myeloid leukaemia
(CML).
Methods:Outcomes of all allogeneic transplants performed after
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